ATI Physical Therapy, Inc. (ATIP) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a 7.1% revenue increase and improved EBITDA margin, the company faces challenges like wage inflation, increased operating costs, and a widening net loss. The lack of a shareholder return plan and unclear management responses in the Q&A add to investor concerns. The absence of new partnerships or significant positive catalysts, combined with financial pressures and uncertainties in reimbursement, suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Key Financial Performance
Net Revenue $190 million, a 7.1% increase year-over-year from $177 million.
Net Patient Revenue $175 million, a 7.7% increase year-over-year.
Other Revenue $15 million, essentially flat year-over-year.
Visits per Day per Clinic 28.3 visits, an increase of 2.4 visits year-over-year from 25.9.
Rate per Visit $109.83, essentially flat year-over-year from $109.90.
Salaries and Related Costs $106 million, an 8.7% increase year-over-year from $97 million, primarily due to more clinical and support staff, wage inflation, and one more paid day.
PT Salaries and Related Costs per Visit $58.29, a 1.4% increase year-over-year from $57.47, driven by wage inflation but partially offset by higher labor productivity.
Rent, Clinic Supplies, Contract Labor and Other Costs $54 million, a 3.4% increase year-over-year from $53 million, with per clinic costs increasing 6.7% year-over-year due to increased contractor usage and higher spend on outside services.
Provision for Doubtful Accounts Approximately $5 million, which is 2.8% of PT revenue compared to 2.1% last year.
SG&A Costs Approximately $24 million, a decrease of $1 million from $25 million in the prior year due to lower corporate insurance costs and lower spend on third-party services.
Non-Cash Long-Lived Impairment Charges $0.1 million during the quarter.
Operating Income $1 million, an increase from a loss of $1 million in the prior year, reflecting higher revenue.
Net Loss $33 million, compared to $15 million in Q3 of 2023.
Adjusted EBITDA $12 million, a 6.4% margin, increased from $9 million or 5.3% margin in the prior year, driven by higher revenue.
Cash Used Year-to-Date Approximately $13 million, compared to $63 million in the prior year.
Operating Cash Used $31 million, compared to $18 million in the prior year, driven by higher accounts receivable and higher revenue.
Cash Used in Investing Activities $9 million, compared to $15 million last year, due to fewer new clinic openings.
Financing Cash Generated $27 million, compared to financing cash used of $31 million last year, primarily driven by a $25 million delayed draw term loan.
Available Liquidity Approximately $23 million as of September 30, 2024.
Operating Highlights
Patient Referrals: Patient referrals per day grew more than 5% year-over-year.
Clinic Visits: Clinics saw over 1400 more patient visits per day compared to Q3 of last year.
Geographic Footprint: Closed eight clinics and divested one as part of the strategic real estate plan.
Clinician Productivity: Clinician productivity improved by more than 0.1 compared to Q3 of last year.
Visits per Clinic: Clinics are seeing over two more visits per day per clinic compared to Q3 of last year.
Employee Engagement: Received overwhelmingly positive feedback in employee engagement survey.
Workforce Expansion: Grew clinician headcount by 3% year-over-year.
Operational Improvements: Focused on continuous operational improvements and better resource allocation.
Risk or Challenges
Labor Market Challenges: The labor market remains challenging, with a mismatch between the supply of physical therapists and the growing demand for PT services. This imbalance is expected to persist for the foreseeable future.
Wage Inflation: Wage inflation continues to be a headwind, with low to mid-single digit increases year-over-year. There are pressures from contractor to full-time clinician transitions, indicating ongoing elevated costs.
Regulatory Risks: There are concerns regarding Medicare reimbursement rates, with potential cuts scheduled for 2025. The company is actively working with organizations to advocate for favorable adjustments.
Operational Costs: Salaries and related costs increased by 8.7% year-over-year, primarily due to wage inflation and an increase in clinical and support staff. This rise in costs could impact overall profitability.
Patient Revenue Stability: Patient revenue per visit remained flat, indicating challenges in the reimbursement landscape, particularly with commercial payers and Medicare.
Cash Flow Concerns: Year-to-date cash used was approximately $13 million, a significant decrease from $63 million in the prior year, but still indicates cash flow management challenges.
Market Dynamics: The company anticipates continued pressure on margins due to elevated wage inflation and operational costs, which may affect future financial performance.
Guidance & Outlook
Revenue Growth: ATI reported a net revenue of $190 million for Q3 2024, a 7.1% increase year-over-year from $177 million.
Adjusted EBITDA: Adjusted EBITDA for Q3 2024 was $12 million, reflecting a 6.4% margin, up from $9 million (5.3% margin) in Q3 2023.
Patient Volume: Patient referrals per day grew more than 5% year-over-year, with clinics seeing over 1400 more patient visits per day compared to Q3 of last year.
Strategic Real Estate Plan: Executed a strategic real estate plan by closing eight clinics and divesting one to refine geographic footprint.
Clinician Headcount: Clinician headcount grew by 3% year-over-year despite challenges in the labor market.
Q4 Revenue Guidance: Anticipated revenue for Q4 2024 is projected to be in the range of $182 million to $192 million.
Q4 Adjusted EBITDA Guidance: Adjusted EBITDA for Q4 2024 is expected to be in the range of $9 million to $14 million.
Wage Inflation Impact: Wage inflation remains a headwind, with low to mid-single digit increases year-over-year.
Patient Revenue per Visit: Patient revenue per visit was flat year-over-year at approximately $109.83.
Shareholder Return Plan
Shareholder Return Plan: None
Key Q&A
Earnings Word Cloud
ATIP Transcript
Despite a 7.1% revenue increase and improved EBITDA margin, the company faces challenges like wage inflation, increased operating costs, and a widening net loss. The lack of a shareholder return plan and unclear management responses in the Q&A add to investor concerns. The absence of new partnerships or significant positive catalysts, combined with financial pressures and uncertainties in reimbursement, suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
The earnings call presents a mixed picture. While there is a 9.2% revenue increase and improved EBITDA, challenges like labor market imbalance, wage inflation, and regulatory changes pose risks. The lack of a share repurchase program and unclear guidance on new products also dampen sentiment. The Q&A reveals some optimism but lacks detail, especially on growth drivers. Given these factors, and without market cap data, the stock price is likely to remain stable in the short term, leading to a neutral prediction.
The earnings call reveals an 8.7% YoY revenue increase, improved EBITDA, and a reduced net loss, indicating strong financial performance. Despite labor market challenges and productivity pressures, management is addressing these issues with targeted strategies. The Q&A section supports this positive outlook, highlighting potential for rate growth and expected improvements in bad debt and productivity. Although some operational challenges remain, the overall sentiment is positive, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
ATIP Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
